Amiodarone (tablet): Difference between revisions
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
'''''For patient information, click <u>[[Amiodarone (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Amiodarone (patient information)|here]]'''''</u>. | ||
{{SB}} | {{SB}} Cordarone, Nexetrone, Pacerone | ||
==Overview== | ==Overview== | ||
| Line 16: | Line 16: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
=== | ===Cordarone<sup>®</sup> tablet FDA Package Insert=== | ||
''' [[Amiodarone indications and usage|Indications and Usage]]''' | ''' [[Amiodarone indications and usage|Indications and Usage]]''' | ||
Revision as of 13:24, 13 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here.
Synonyms / Brand Names: Cordarone, Nexetrone, Pacerone
Overview
Category
FDA Package Insert
Cordarone® tablet FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
 |
AMIODARONE HYDROCHLORIDE injection® FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages